Skip to Content

Join the 'Hemophilia B' group to help and get support from people like you.

Hemophilia B News

Another Gene Therapy Breakthrough Against Hemophilia

Posted 10 Dec 2017 by Drugs.com

SATURDAY, Dec. 9, 2017 – Coming just days after reports of a gene therapy that pushed the bleeding disorder hemophilia B into remission, new research suggests the same could be true for adults with the "A" form of the disease. That's significant because, due to the complexities of the gene responsible for hemophilia A, experts had thought it might be far more resistant to gene-based treatment. ...

Gene Therapy May Allow Hemophilia Patients to Go Without Meds

Posted 7 Dec 2017 by Drugs.com

WEDNESDAY, Dec. 6, 2017 – Gene therapy has helped 10 men with a form of the bleeding disorder hemophilia produce a critical blood clotting factor. This could eliminate the need for tedious and costly standard treatments, researchers report. While saying the one-time gene therapy was an ideal treatment goal because of its effects, the researchers stopped short of calling it a cure for hemophilia ...

Is Blood Donated by Mothers Less Safe for Men?

Posted 17 Oct 2017 by Drugs.com

TUESDAY, Oct. 17, 2017 – Men who receive blood donated by previously pregnant women may face an increased risk of death following the transfusion, a new study from the Netherlands suggests. Males transfused with blood from a woman with a history of pregnancy appear to be 13 percent overall more likely to die in coming years, compared with those who received blood from another man, said ...

FDA Approves Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) for Patients with Hemophilia B

Posted 27 Jun 2017 by Drugs.com

PLAINSBORO, N.J., May 31, 2017 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) for the treatment of adults and children with hemophilia B. Hemophilia B is a chronic and inherited bleeding disorder that affects approximately 5,000 people in ...

Researchers Develop Potential Oral Treatment for Hemophilia

Posted 30 Dec 2016 by Drugs.com

THURSDAY, Dec. 29, 2016 – People with hemophilia have to endure painful injections every few days to stay alive, but a newly developed treatment may one day offer a simpler, cheaper and less painful alternative. University of Texas at Austin researchers created an oral treatment for one type of hemophilia, which is a serious, genetic bleeding disorder. But, the treatment is still in the early ...

Gene Therapy Offers Hope to Some Hemophilia Patients

Posted 6 Dec 2016 by Drugs.com

TUESDAY, Dec. 6, 2016 – Preliminary research suggests that a single dose of an experimental gene therapy may help patients with hemophilia B. As explained by the National Hemophilia Foundation, hemophilia B is a genetic disorder where people lack a protein needed for blood clotting called factor IX, or that the type of factor IX they produce is defective. The condition can lead to excess ...

Two New Findings Offer Hope for Those With Severe Hemophilia

Posted 26 May 2016 by Drugs.com

WEDNESDAY, May 25, 2016 – Two new studies could pave the way to major changes in how doctors treat severe cases of hemophilia – a rare genetic disorder that can cause uncontrolled bleeding. Both studies tackle a key challenge: Up to one-third of children with severe hemophilia develop antibodies against the standard therapy. But one study highlights the value of an old therapy, while the other ...

Review Finds Mixed Success With Hemophilia Treatment

Posted 16 Mar 2016 by Drugs.com

WEDNESDAY, March 16, 2016 – Though the past 50 years have brought major treatment advances, men with severe hemophilia are still at high risk for bleeding and physical disability, experts say. Hemophilia is a genetic disease that prevents blood from clotting normally, leading to an increased risk of serious bleeding. More common in men than in women, it affects about one out of every 5,000 men, ...

Idelvion Approved for Hemophilia B

Posted 8 Mar 2016 by Drugs.com

MONDAY, March 7, 2016 – Idelvion has been approved by the U.S. Food and Drug Administration to replace a deficient blood clotting factor among people with hemophilia B. The product – which has the generic name of "coagulation Factor IX, albumin fusion protein" – is created using recombinant DNA technology that links the blood clotting protein known as Factor IX to another blood protein, ...

FDA Approves Idelvion (coagulation factor IX (recombinant), albumin fusion protein) to Treat Patients with Hemophilia B

Posted 8 Mar 2016 by Drugs.com

March 4, 2016 – The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood. “The ...

Kids' Hemophilia Drugs a Big Part of State Medicaid Spending

Posted 31 Jul 2015 by Drugs.com

FRIDAY, July 31, 2015 – Treatment costs for one childhood illness, hemophilia, may use up a big chunk of a state's Medicaid budget, a new study out of California shows. The researchers found that treatments for hemophilia – a rare, inherited disorder in which blood does not clot normally – accounted for the largest share of spending on outpatient drugs among publicly insured children in ...

Emergent BioSolutions Announces FDA Approval of Ixinity [coagulation factor IX (recombinant)] for Hemophilia B

Posted 1 May 2015 by Drugs.com

GAITHERSBURG, Md., April 30, 2015 (GLOBE NEWSWIRE) – Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved Ixinity [coagulation factor IX (recombinant)], an intravenous recombinant human coagulation factor IX therapeutic for the control and prevention of bleeding episodes and for perioperative management in adults and children, ≥12 y ...

Long-Acting Clotting Agent Alprolix Approved for Form of Hemophilia

Posted 31 Mar 2014 by Drugs.com

MONDAY, March 31, 2014 The drug Alprolix has been approved by the U.S. Food and Drug Administration as the first long-acting hemophilia B clotting agent, the FDA said in a news release. The product, formally known as "coagulation factor IX recombinant Fc Fusion protein" is the first hemophilia B remedy designed to require less frequent injections than prior treatments, the FDA said. It was ...

FDA Approves Alprolix (recombinant coagulation factor IX) for patients with Hemophilia B

Posted 28 Mar 2014 by Drugs.com

March 28, 2014 – The U.S. Food and Drug Administration today approved Alprolix, Coagulation Factor IX (Recombinant), Fc Fusion Protein, for use in adults and children who have Hemophilia B. Alprolix is the first Hemophilia B treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding. Alprolix is approved to help control and prevent bleeding ...

FDA Approves Rixubis - First Recombinant Coagulation Factor IX For Use in Preventing Bleeding Episodes

Posted 27 Jun 2013 by Drugs.com

June 27, 2013 – The U.S. Food and Drug Administration yesterday approved Rixubis [Coagulation Factor IX (Recombinant)] for use in people with hemophilia B who are 16 years of age and older. Rixubis is indicated for the control and prevention of bleeding episodes, perioperative (period extending from the time of hospitalization for surgery to the time of discharge) management, and routine use to ...

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Hemophilia

Related Drug Support Groups

Rixubis, coagulation factor ix, Bebulin VH, Idelvion, Bebulin, Ixinity, Alprolix, NovoSeven RT, Profilnine SD, view more... coagulation factor viia, Konyne 80, BeneFIX 250 Int'l Units, Alphanine SD, Mononine, Proplex T, BeneFix, factor ix complex, Rebinyn